Showing results (11-20 of 45) with videos related to
Sort By:
Pageof 5
Anticancer Research|September 12, 2013
PTK7 expression in triple-negative breast cancerBeyhan Ataseven, Regina Angerer, Ronald Kates, et al.Onkologie|September 13, 2007
Improvement of safety profile of docetaxel by weekly administration in patients with metastatic breast cancerMathias Warm, Frank Nawroth, Ralf Ohlinger, et al.Biological Chemistry|August 10, 2006
Disease processes may be reflected by correlations among tissue kallikrein proteases but not with proteolytic factors uPA and PAI-1 in primary ovarian carcinomaJulia Dorn, Nadia Harbeck, Ronald Kates, et al.Clinical Cancer Research : an Official Journal of the American Association for Cancer Research|August 24, 2005
Analysis of the DPYD gene implicated in 5-fluorouracil catabolism in a cohort of Caucasian individualsKatharina Seck, Silvia Riemer, Ronald Kates, et al.European Journal of Cancer (Oxford, England : 1990)|June 21, 2016
European cost-effectiveness study of uPA/PAI-1 biomarkers to guide adjuvant chemotherapy decisions in breast cancerSophie Marguet, Chafika Mazouni, Bram L T Ramaekers, et al.Oncology Letters|December 2, 2014
OVSCORE - a validated score to identify ovarian cancer patients not suitable for primary surgeryJulia Dorn, Holger Bronger, Ronald Kates, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|July 11, 2006
FGFR4 Arg388 allele is associated with resistance to adjuvant therapy in primary breast cancerChristoph Thussbas, Jorg Nahrig, Sylvia Streit, et al.Journal of Personalized Medicine|September 28, 2021
Molecular Prognostic Factors for Distant Metastases in Premenopausal Patients with HR+/HER2- Early Breast CancerHua Ni, Jörg Kumbrink, Doris Mayr, et al.Journal of the National Cancer Institute|December 12, 2017
Comparison of Neoadjuvant Nab-Paclitaxel+Carboplatin vs Nab-Paclitaxel+Gemcitabine in Triple-Negative Breast Cancer: Randomized WSG-ADAPT-TN Trial ResultsOleg Gluz, Ulrike Nitz, Cornelia Liedtke, et al.Journal of Clinical Oncology : Official Journal of the American Society of Clinical Oncology|November 11, 2009
Y-box-binding protein YB-1 identifies high-risk patients with primary breast cancer benefiting from rapidly cycled tandem high-dose adjuvant chemotherapyOleg Gluz, Karin Mengele, Manfred Schmitt, et al.Pageof 5